ArticleDermatology and therapy2026

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.

Jerry Bagel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.